Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve, AKL, Astellas, Direct Biologics, Kezar, Lilly, Merck, Merck KGaA, Oncologie, Roche.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Apnimed, Epygenix, Intensity, Mimedx, Novartis, Octapharma, Principia, Rhovac, Rigel, Virometix.
A new randomized controlled trial (RCT) of COVID-19 convalescent plasma (CCP) treatment for moderately ill COVID-19 patients run at 39 Indian hospitals found no association between CCP therapy and reduced mortality or progression to severe disease.
The positive interim 24-week liver biopsy results from Arrowhead Pharmaceuticals Inc.’s open-label phase II of its RNAi-based liver-targeted therapeutic, ARO-AAT, came as a surprise to the developers.
DUBLIN – Adrenomed AG reported its anti-adrenomedullin antibody, adrecizumab, attained an absolute reduction of 9% in mortality as compared with placebo at both 14 and 28 days (D28) after treatment in a phase II trial in a large subgroup of patients with septic shock.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adrenomed, Aim Immunotech, Algernon, Arcutis, Arena, Arrowhead, Aveo, Eli Lilly, Exicure, Galera, Genelux, Heron, Horizon, Immune-Onc, Knopp, Menarini, Ryvu, Springworks, Verastem, Verona.
HONG KONG – Interim results of a phase I study CT-P59, an anti-COVID-19 monoclonal antibody being developed by Incheon, South Korea-based Celltrion Inc., have confirmed the candidate’s safety, tolerability and pharmacokinetics in healthy subjects, giving the company confidence to ramp up production of the experimental antiviral.
HONG KONG – Sanofi SA has finally ended its clinical development of Hanmi Pharmaceutical Co. Ltd.’s efpeglenatide as a type 2 diabetes treatment, and the Korean firm is now considering how to move forward with developing the once-weekly GLP-1 receptor agonist, which employs Hanmi's Lapscovery delivery technology.
Shares of Marinus Pharmaceuticals Inc. climbed 51.7% to close at $3.20 on Sept. 15 following news that the company's sole clinical asset, ganaxolone, met the primary endpoint of its phase III Marigold study in CDKL5 deficiency disorder, a rare genetic condition that can leave children unable to walk, talk or feed themselves.
RSS
